Haleos Labs Limited (NSE:SMSLIFE)

Market Cap	3.39B
Revenue (ttm)	3.35B
Net Income (ttm)	173.16M
Shares Out	3.02M
EPS (ttm)	57.27
PE Ratio	19.60
Forward PE	n/a
Dividend	1.50 (0.13%)
Ex-Dividend Date	Sep 24, 2025

Volume	490
Average Volume	613
Open	1,148.50
Previous Close	1,140.60
Day's Range	1,113.00 - 1,148.50
52-Week Range	959.80 - 1,680.00
Beta	0.26
RSI	44.27
Earnings Date	Nov 13, 2025

About Haleos Labs

Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesci...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 592
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SMSLIFE

Financial Performance

In 2024, Haleos Labs's revenue was 3.45 billion, an increase of 12.67% compared to the previous year's 3.06 billion. Earnings were 201.09 million, an increase of 121.15%.